Oncología

Resultados: 391
Tipo Título / Nombre Autor(es) Año
Constructing a high-definition patient-digital twin (PDT) in treatment-naïve women with advanced cancer Garma LD, Jiménez D, Vicente Baz D..., González S 2024
Treatment outcomes of patients with anaplastic thyroid carcinoma (atc): Multicentric data from spanish national registry (regetne-tiroides) Rodellar JM, Hernando Cubero J, García Álvarez A..., Ayala de Miguel P 2024
Sequence matters: Impact of first-line response in overall therapeutic outcome in differentiated thyroid cancer. Data from the Spanish national registry of thyroid cancer (REGETNE-Tiroides) Pérez Fernández S., Hernando Cubero J, García Álvarez A..., Ayala de Miguel P 2024
Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study Alés-Martínez JE, Balmaña J, Sánchez-Rovira P, Salvador Bofill FJ, García Sáenz JÁ..., López-Ceballos MH, et al 2024
Manejo de reacciones infusionales en la terapia antineoplásica Espacio Santos PM 2024
Long-term responders (LTR) with niraparib maintenance in platinum-sensitive recurrent high-grade serous ovarian cancer (PSROC) focusing on subsequent therapies and postprogression outcomes (GEICO-88R study) Cuevas Banuelos JF, García García Y, Yubero Esteban A, Gallego Martinez A..., González S, et al 2024
No More Training: SAM’s Zero-Shot Transfer Capabilities for Cost-Efficient Medical Image Segmentation Gutiérrez JD, Rodríguez Echevarria R, Delgado E, Suero Rodrigo MA, Sánchez Figueroa F 2024
Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence Cervantes A, Tabernero J, Garcia-Carbonero R, Sastre J, Feliu J..., Muñoz J, et al 2024
Ipatasertib (IPA) combined with non-taxane chemotherapy (CT) for patients (pts) with previously treated advanced triple-negative breast cancer (aTNBC): The PATHFINDER phase IIa trial López Miranda E, Pérez García JM, Gion M..., González Santiago S 2024
Real-world effectiveness and safety of dabrafenib-trametinib as first-line of treatment for BRAF mutated metastatic melanoma: Results of the study GEM1801 Berciano Guerrero MA, Pérez Ruiz E, Muñoz Couselo E, Manzano JL..., Ayala de Miguel P 2024